GRADE 2 was adverse symptoms, together with the evidence of biomarkers, such as sensitization identified by SPT or sIgE; GRADE 3 came from the data about self-reported results alone, as well as only evidence of IgE data to identify food allergy, and patients with allergy were identified by retrospective review of medical records. This evidence concerns the gene IGHE and food allergy.